Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for December 3 at 9:30 a.m. PT / 12:30 p.m. ET. Interested parties can access a live webcast and replay of the event through the company's investor relations website under the 'Events and Presentations' section.
Avidity Biosciences (Nasdaq: RNA), sviluppatore di Coniugati di Oligonucleotidi Anticorpali (AOCs™), ha annunciato la sua partecipazione alla prossima 7a Conferenza Annuale Evercore ISI HealthCONx. La presentazione è in programma per il 3 dicembre alle 9:30 ora del Pacifico / 12:30 ora dell'Est. Le parti interessate possono accedere a una diretta streaming e alla registrazione dell'evento attraverso il sito web delle relazioni con gli investitori dell'azienda nella sezione 'Eventi e Presentazioni'.
Avidity Biosciences (Nasdaq: RNA), desarrollador de Conjugados de Oligonucleótidos de Anticuerpos (AOCs™), ha anunciado su participación en la próxima 7ª Conferencia Anual Evercore ISI HealthCONx. La presentación está programada para el 3 de diciembre a las 9:30 a.m. PT / 12:30 p.m. ET. Las partes interesadas pueden acceder a una transmisión en vivo y reproducción del evento a través del sitio web de relaciones con inversores de la empresa en la sección 'Eventos y Presentaciones'.
Avidity Biosciences (Nasdaq: RNA), 항체 올리고뉴클레오타이드 결합체(AOCs™) 개발자로, 다가오는 제7회 연례 Evercore ISI HealthCONx 컨퍼런스에 참여한다고 발표했습니다. 발표는 12월 3일 오전 9:30 PT / 오후 12:30 ET로 예정되어 있습니다. 관심 있는 분들은 회사의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션을 통해 생중계 및 이벤트 재생에 접근할 수 있습니다.
Avidity Biosciences (Nasdaq: RNA), développeur de Conjugués d'Oligonucléotides d'Anticorps (AOCs™), a annoncé sa participation à la prochaine 7e Conférence Annuelle Evercore ISI HealthCONx. La présentation est prévue pour le 3 décembre à 9h30 PT / 12h30 ET. Les parties intéressées peuvent accéder à un webcast en direct et à un replay de l'événement via le site web des relations investisseurs de l'entreprise dans la section 'Événements et Présentations'.
Avidity Biosciences (Nasdaq: RNA), Entwickler von Antikörper-Oligonukleotid-Konjugaten (AOCs™), hat seine Teilnahme an der bevorstehenden 7. jährlichen Evercore ISI HealthCONx-Konferenz angekündigt. Die Präsentation ist für den 3. Dezember um 9:30 Uhr PT / 12:30 Uhr ET angesetzt. Interessierte Parteien können über die Investor-Relations-Website des Unternehmens im Abschnitt 'Veranstaltungen und Präsentationen' auf einen Live-Stream und eine Wiederholung der Veranstaltung zugreifen.
- None.
- None.
- 7th Annual Evercore ISI HealthCONx Conference on December 3 at 9:30 a.m. PT / 12:30 p.m. ET
A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302314600.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the Evercore ISI HealthCONx Conference 2024?
Where can I watch Avidity Biosciences' (RNA) Evercore Conference presentation?
What type of therapeutics does Avidity Biosciences (RNA) develop?
